# Filing Detail

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-23-000048
Filing Date
2023-08-14
Accepted
2023-08-14 09:49:22
Documents
7
Period of Report
2023-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 6-K | q22023form6-k.htm | 6-K | 22465
2 | EX-99.1 2023 SECOND QUARTER INTERIM FINANCIAL STATEMENTS | ex991-interimfsjune302023.htm | EX-99.1 | 363319
3 | EX-99.2 2023 SECOND QUARTER MD&A | ex992-q22023mda.htm | EX-99.2 | 240452
4 | EX-99.3 Q2 2023 CERTIFICATION CEO | ex993-q22023certificationx.htm | EX-99.3 | 14384
5 | EX-99.4 Q2 2023 CERTIFICATION CFO | ex994-q22023certificationx.htm | EX-99.4 | 14281
6 |  | oncolyticslogotaglineblueaa.jpg | GRAPHIC | 355294
7 |  | q22023pipeline4a.jpg | GRAPHIC | 529098
| Complete submission text file | 0001129928-23-000048.txt |  | 1823641

Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 231166902
SIC: 2834 Pharmaceutical Preparations